Combined regression score predicts outcome after neoadjuvant treatment of oesophageal cancer

被引：5

作者：

Damanakis, A. I. ^{[1
,2
]}

Gebauer, F. ^{[3
]}

Stapper, A. ^{[1
,2
]}

Schloesser, H. A. ^{[1
,2
,4
]}

Ghadimi, M. ^{[5
]}

Schmidt, T. ^{[1
,2
]}

Schiffmann, L. M. ^{[1
,2
]}

Fuchs, H. ^{[1
,2
]}

Zander, T. ^{[2
,6
]}

Quaas, A. ^{[2
,7
]}

Bruns, C. J. ^{[1
,2
]}

Schroeder, W. ^{[1
,2
]}

机构：

[1] Univ Cologne, Fac Med, Dept Gen Visceral Canc & Transplantat Surg, Cologne, Germany

[2] Univ Hosp Cologne, Cologne, Germany

[3] Helios Univ, Hosp Wuppertal, Dept Gen & Visceral Surg, Wuppertal, Germany

[4] Ctr Mol Med Cologne, Fac Med, Cologne, Germany

[5] Stadt Soest Hosp, Dept Gen Visceral & Endocrine Surg, Soest, Germany

[6] Univ Cologne, Gastrointestinal Canc Grp Cologne GCGC, Fac Med, Ctr Integrated Oncol Aachen Bonn Cologne,Dept Int, Cologne, Germany

[7] Univ Cologne, Inst Pathol, Fac Med, Cologne, Germany

来源：

BRITISH JOURNAL OF CANCER | 2023年 / 128卷 / 11期

关键词：

CHEMORADIOTHERAPY PLUS SURGERY; TUMOR-REGRESSION; PREOPERATIVE CHEMORADIOTHERAPY; RESECTED ESOPHAGEAL; SURVIVAL; ADENOCARCINOMAS; CHEMORADIATION; CHEMOTHERAPY; OXALIPLATIN; MULTICENTER;

D O I：

10.1038/s41416-023-02232-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundHistopathologic regression following neoadjuvant treatment (NT) of oesophageal cancer is a prognostic factor of survival, but the nodal status is not considered. Here, a score combining both to improve prediction of survival after neoadjuvant therapy is developed.MethodsSeven hundred and fifteen patients with oesophageal squamous cell (SCC) or adenocarcinoma (AC) undergoing NT and esophagectomy were analysed. Histopathologic response was classified according to percentage of vital residual tumour cells (VRTC): complete response (CR) without VRTC, major response with <10% VRTC, minor response with >10% VRTC. Nodal stage was classified as ypN0 and ypN+. Kaplan-Meier and Cox regression were used for survival analysis.ResultsSurvival analysis identified three groups with significantly different mortality risks: (1) low-risk group for CR (ypT0N0) with 72% 5-year overall survival (5y-OS), (2) intermediate-risk group for minor/major responders and ypN0 with 59% 5y-OS, and (3) high-risk group for minor/major responders and ypN+ with 20% 5y-OS (p < 0.001). Median survival in AC and SCC cohorts were comparable (3.8 (CI 95%: 3.1, 5.3) vs. 4.6 years (CI 95%: 3.3, not reached), p = 0.3).ConclusionsHistopathologic regression and nodal status should be combined for estimating AC and SCC prognosis. Poor survival in the high-risk group highlights need for adjuvant therapy.

引用

页码：2025 / 2035

页数：11

共 44 条

[1] Esophageal and Esophagogastric Junction Cancers, Version 2.2019 [J].

Ajani, Jaffer A. ;

D'Amico, Thomas A. ;

Bentrem, David J. ;

Chao, Joseph ;

Corvera, Carlos ;

Das, Prajnan ;

Denlinger, Crystal S. ;

Enzinger, Peter C. ;

Fanta, Paul ;

Farjah, Farhood ;

Gerdes, Hans ;

Gibson, Michael ;

Glasgow, Robert E. ;

Hayman, James A. ;

Hochwald, Steven ;

Hofstetter, Wayne L. ;

Ilson, David H. ;

Jaroszewski, Dawn ;

Johung, Kimberly L. ;

Keswani, Rajesh N. ;

Kleinberg, Lawrence R. ;

Leong, Stephen ;

Ly, Quan P. ;

Matkowskyj, Kristina A. ;

McNamara, Michael ;

Mulcahy, Mary F. ;

Paluri, Ravi K. ;

Park, Haeseong ;

Perry, Kyle A. ;

Pimiento, Jose ;

Poultsides, George A. ;

Roses, Robert ;

Strong, Vivian E. ;

Wiesner, Georgia ;

Willett, Christopher G. ;

Wright, Cameron D. ;

McMillian, Nicole R. ;

Pluchino, Lenora A. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (07) :855-883

[2] Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J].

Al-Batran, Salah-Eddin ;

Homann, Nils ;

Pauligk, Claudia ;

Goetze, Thorsten O. ;

Meiler, Johannes ;

Kasper, Stefan ;

Kopp, Hans-Georg ;

Mayer, Frank ;

Haag, Georg Martin ;

Luley, Kim ;

Lindig, Udo ;

Schmiegel, Wolff ;

Pohl, Michael ;

Stoehlmacher, Jan ;

Folprecht, Gunnar ;

Probst, Stephan ;

Prasnikar, Nicole ;

Fischbach, Wolfgang ;

Mahlberg, Rolf ;

Trojan, Joerg ;

Koenigsmann, Michael ;

Martens, Uwe M. ;

Thuss-Patience, Peter ;

Egger, Matthias ;

Block, Andreas ;

Heinemann, Volker ;

Illerhaus, Gerald ;

Moehler, Markus ;

Schenk, Michael ;

Kullmann, Frank ;

Behringer, Dirk M. ;

Heike, Michael ;

Pink, Daniel ;

Teschendorf, Christian ;

Loehr, Carmen ;

Bernhard, Helga ;

Schuch, Gunter ;

Rethwisch, Volker ;

von Weikersthal, Ludwig Fischer ;

Hartmann, Joerg T. ;

Kneba, Michael ;

Daum, Severin ;

Schulmann, Karsten ;

Weniger, Joerg ;

Belle, Sebastian ;

Gaiser, Timo ;

Oduncu, Fuat S. ;

Guentner, Martina ;

Hozaeel, Wael ;

Reichart, Alexander .

LANCET, 2019, 393 (10184) :1948-1957

[3] The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI [J].

Al-Batran, Salah-Eddin ;

Goetze, Thorsten O. ;

Mueller, Daniel W. ;

Vogel, Arndt ;

Winkler, Michael ;

Lorenzen, Sylvie ;

Novotny, Alexander ;

Pauligk, Claudia ;

Homann, Nils ;

Jungbluth, Thomas ;

Reissfelder, Christoph ;

Caca, Karel ;

Retter, Steffen ;

Horndasch, Eva ;

Gumpp, Julia ;

Bolling, Claus ;

Fuchs, Karl-Hermann ;

Blau, Wolfgang ;

Padberg, Winfried ;

Pohl, Michael ;

Wunsch, Andreas ;

Michl, Patrick ;

Mannes, Frank ;

Schwarzbach, Matthias ;

Schmalenberg, Harald ;

Hohaus, Michael ;

Scholz, Christian ;

Benckert, Christoph ;

Knorrenschild, Jorge Riera ;

Kanngiesser, Veit ;

Zander, Thomas ;

Alakus, Hakan ;

Hofheinz, Ralf-Dieter ;

Roedel, Claus ;

Shah, Manish A. ;

Sasako, Mitsuru ;

Lorenz, Dietmar ;

Izbicki, Jakob ;

Bechstein, Wolf O. ;

Lang, Hauke ;

Moenig, Stefan P. .

BMC CANCER, 2017, 17

[4] Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial [J].

Al-Batran, Salah-Eddin ;

Hofheinz, Ralf D. ;

Pauligk, Claudia ;

Kopp, Hans-Georg ;

Haag, Georg Martin ;

Luley, Kim Barbara ;

Meiler, Johannes ;

Homann, Nils ;

Lorenzen, Sylvie ;

Schmalenberg, Harald ;

Probst, Stephan ;

Koenigsmann, Michael ;

Egger, Matthias ;

Prasnikar, Nicole ;

Caca, Karel ;

Trojan, Joerg ;

Martens, Uwe M. ;

Block, Andreas ;

Fischbach, Wolfgang ;

Mahlberg, Rolf ;

Clemens, Michael ;

Illerhaus, Gerald ;

Zirlik, Katja ;

Behringer, Dirk M. ;

Schmiegel, Wolff ;

Pohl, Michael ;

Heike, Michael ;

Ronellenfitsch, Ulrich ;

Schuler, Martin ;

Bechstein, Wolf O. ;

Koenigsrainer, Alfred ;

Gaiser, Timo ;

Schirmacher, Peter ;

Hozaeel, Wael ;

Reichart, Alexander ;

Goetze, Thorsten O. ;

Sievert, Mark ;

Jaeger, Elke ;

Moenig, Stefan ;

Tannapfel, Andrea .

LANCET ONCOLOGY, 2016, 17 (12) :1697-1708

[5] Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy [J].

Becker, K ;

Mueller, JD ;

Schulmacher, C ;

Ott, K ;

Fink, U ;

Busch, R ;

Böttcher, K ;

Siewert, JR ;

Höfler, H .

CANCER, 2003, 98 (07) :1521-1530

[6]

Brierley JD GM, 2016, TNM classification of malignant tumors, V8

[7] Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial [J].

Davarzani, Nasser ;

Hutchins, Gordon G. A. ;

West, Nicholas P. ;

Hewitt, Lindsay C. ;

Nankivell, Matthew ;

Cunningham, David ;

Allum, William H. ;

Smyth, Elizabeth ;

Valeri, Nicola ;

Langley, Ruth E. ;

Grabsch, Heike I. .

HISTOPATHOLOGY, 2018, 72 (07) :1180-1188

[8] Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma [J].

Davies, A. R. ;

Myoteri, D. ;

Zylstra, J. ;

Baker, C. R. ;

Wulaningsih, W. ;

Van Hemelrijck, M. ;

Maisey, N. ;

Allum, W. H. ;

Smyth, E. ;

Gossage, J. A. ;

Lagergren, J. ;

Cunningham, D. ;

Green, M. .

BRITISH JOURNAL OF SURGERY, 2018, 105 (12) :1639-1649

[9] Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial [J].

Eyck, Ben M. ;

van Lanschot, J. Jan B. ;

Hulshof, Maarten C. C. M. ;

van der Wilk, Berend J. ;

Shapiro, Joel ;

van Hagen, Pieter ;

Henegouwen, Mark I. van Berge ;

Wijnhoven, Bas P. L. ;

van Laarhoven, Hanneke W. M. ;

Nieuwenhuijzen, Grard A. P. ;

Hospers, Geke A. P. ;

Bonenkamp, Johannes J. ;

Cuesta, Miguel A. ;

Blaisse, Reinoud J. B. ;

Busch, Olivier R. ;

Creemers, Geert-Jan M. ;

Punt, Cornelis J. A. ;

Plukker, John Th M. ;

Verheul, Henk M. W. ;

Bilgen, Ernst J. Spillenaar ;

van der Sangen, Maurice J. C. ;

Rozema, Tom ;

Ten Kate, Fiebo J. W. ;

Beukema, Jannet C. ;

Piet, Anna H. M. ;

van Rij, Caroline M. ;

Reinders, Janny G. ;

Tilanus, Hugo W. ;

Steyerberg, Ewout W. ;

van der Gaast, Ate .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18) :1995-+

[10] Prognostic relevance of lymph node regression on survival in esophageal cancer: a systematic review and meta-analysis [J].

Hagens, Eliza ;

Tukanova, Karina ;

Jamel, Sara ;

Henegouwen, Mark van Berge ;

Hanna, George B. ;

Gisbertz, Suzanne ;

Markar, Sheraz R. .

DISEASES OF THE ESOPHAGUS, 2022, 35 (01)

← 1 2 3 4 5 →